REFERENCES

1. Bettendorf O, Piffkò J, Bànkfalvi A. Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 2004;40:110-9.

2. Nagler RM. Molecular aspects of oral cancer. Anticancer Res 2002;22:2977-80.

3. Zbären P, Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 1987;113:762-4.

4. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52:195-215.

5. Feller L, Lemmer J. Oral squamous cell carcinoma: epidemiology, clinical presentation and treatment. J Cancer Ther 2012;3:263-8.

6. Facompre N, Nakagawa H, Herlyn M, Basu D. Stem-like cells and therapy resistance in squamous cell carcinomas. Adv Pharmacol 2012;65:235-65.

7. Cohen EE. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin Oncol 2004;31:755-68.

8. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinicopathological applications. Oral Oncol 2000;36:404-13.

9. Nagpal JK, Das BR. Oral cancer: reviewing the present understanding of its molecular mechanisms and exploring the future directions for its effective management. Oral Oncol 2003;39:213-21.

10. Nagai MA. Genetic alterations in head and neck squamous cell carcinomas. Braz J Med Biol Res 1999;32:897-904.

11. Vilenchik MM, Knudson AG Jr. Inverse radiation dose-rate effects on somatic and germ-line mutations and DNA damage rates. Proc Natl Acad Sci U S A 2000;97:5381-6.

12. Arnott RD, Bernstein PL. What risk premium is "normal"? Financial Analyst J 2002;58:64-85.

13. Petrini JH. The Mre11 complex and ATM: collaborating to navigate S phase. Curr Opin Cell Biol 2000;12:293-6.

14. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev 2000;10:144-50.

15. D'Amours D, Jackson SP. The Mre11 complex: at the crossroads of DNA repair and checkpoint signaling. Nat Rev Mol Cell Biol 2002;3:317-27.

16. Cerosaletti KM, Lange E, Stringham HM, Weemaes CM, Smeets D, Sölder B, Belohradsky BH, Taylor AM, Karnes P, Elliott A, Komatsu K, Gatti RA, Boehnke M, Concannon P. Fine localization of the Nijmegen breakage syndrome gene to 8q21: evidence for a common founder haplotype. Am J Hum Genet 1998;63:125-34.

17. Nelms BE, Maser RS, MacKay JF, Lagally MG, Petrini JH. In situ visualization of DNA double-strand break repair in human fibroblasts. Science 1998;280:590-2.

18. Pandita TK, Pathak S, Geard CR. Chromosome end associations, telomeres and telomerase activity in ataxia telangiectasia cells. Cytogenet Cell Genet 1995;71:86-93.

19. Metcalfe JA, Parkhill J, Campbell L, Stacey M, Biggs P, Byrd PJ, Taylor AM. Accelerated telomere shortening in ataxia telangiectasia. Nat Genet 1996;13:350-3.

20. Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH, Kastan MB. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 2000;404:613-7.

21. Zhao S, Weng YC, Yuan SS, Lin YT, Hsu HC, Lin SC, Gerbino E, Song MH, Zdzienicka MZ, Gatti RA, Shay JW, Ziv Y, Shiloh Y, Lee EY. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature 2000;405:474-7.

22. Wu X, Ranganathan V, Weisman DS, Heine WF, Ciccone DN, O' Neill TB, Crick KE, Pierce KA, Lane WS, Rathbun G, Livingston DM, Weaver DT. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 2000;405:477-82.

23. Stumm M, von Ruskowsky A, Siebert R, Harder S, Varon R, Wieacker P, Schlegelberger B. No evidence for deletions of the NBS1 gene in lymphomas. Cancer Genet Cytogenet 2001;26:60-2.

24. Varon R, Reis A, Henze G, von Einsiedel HG, Sperling K, Seeger K. Mutations in the Nijmegen Breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res 2001;61:3570-2.

25. Plisiecka-Halasa J, Dansonka-Mieszkowska A, Rembiszewska A, Bidziński M, Steffen J, Kupryjańczyk J. Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumors. Ann Hum Genet 2002;66:353-9.

26. Wilda M, Demuth I, Concannon P, Sperling K, Hameister H. Expression pattern of the Nijmegen breakage syndrome gene, Nbs1, during murine development. Hum Mol Genet 2000;9:1739-44.

27. Featherstone C, Jackson SP. DNA repair: The Nijmegen breakage syndrome protein. Curr Biol 1998;8:622-5.

28. Digweed M, Reis A, Sperling K. Nijmegen breakage syndrome: consequences of defective DNA double strand break repair. Bioessays 1999;21:649-56.

29. Stracker TH, Petrini JH. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol 2011;12:90-103.

30. Hsu DS, Chang SY, Liu CJ, Tzeng CH, Wu KJ, Kao JY, Yang MH. Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity. Cancer Sci 2010;101:1029-37.

31. Ali-Fehmi R, Chatterjee M, Ionan A, Levin NK, Arabi H, Bandyopadhyay S, Shah JP, Bryant CS, Hewitt SM, O' Rand MG, Alekseev OM, Morris R, Munkarah A, Abrams J, Tainsky MA. Analysis of the expression of human tumor antigens in ovarian cancer tissues. Cancer biomark 2010;6:33-48.

32. Hall J, Angèle S. Radiation, DNA damage and cancer. Mol Med Today 1999;5:157-64.

33. Ehlers JP, Harbour JW. NBS1 expression as a prognostic marker in uveal melanoma. Clin Cancer Res 2005;11:1849-53.

34. Angèle S, Treilleux I, Brémond A, Tanière P, Hall J. Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. Histopathology 2003;43:347-53.